Start Your Search
MINI 21 - Novel Targets (ID 133)
- Event: WCLC 2015
- Type: Mini Oral
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
MINI21.03 - CACNA2D1 Is a Novel Biomarker for Tumor Initiating Cells and Has Therapeutic Effect in Non-Small Cell Lung Cancer (ID 3074)
16:45 - 18:15 | Author(s): Y. Ma
Tumor initiating cells (TICs) are a small subpopulation within cancer that is thought to be resistant to conventional therapies and capable of reinitiating tumors. However, only a few biomarkers of TICs have been well elucidated.
By the methods of QPCR, FACS, western blot, colony formation and statistic analysis, we have investigated whether CACNA2D1 (α2δ1) to enrich TICs of non-small cell lung cancer (NSCLC) and and tharget therapy of its antibody.
In comparison to α2δ1[-], α2δ1[+] cells demonstrated greater TICs properties with higher potential of self-renewal, differentiation and reconstituting tumors. Following treatment, these cells were enriched in clinical samples. We verified a monoclonal antibody of α2δ1 mAb which targets to α2δ1 had therapeutic treatment to TICs of NSCLC and further α2δ1 mAb combined with the common anti-cancer drug of carboplatin was obtained to suppress the established xenograft tumors. Importantly, the disease free survival and overall survival of NSCLC patients with increased α2δ1 expression was significantly shorter than that of patients with decreased expression. Mechanically, our results showed that a role of α2δ1 in up-regulating stemness of NSCLC cells was associated with NOTCH signaling.
Collectively, our data indicate that α2δ1 could be used as a marker for identifying TICs of NSCLC and targeting these cells might provide a way to treat this disease.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.